|
HbA1c
|
|
|
| Diabetes patients with HbA1c test who are treated with glucose lowering drug(s) |
First HbA1c test in 2007 |
Glucose lowering drug prescription within last 3 months of 2007 |
| Diabetes patients with HbA1c >7% who are treated with glucose lowering drug(s) |
First HbA1c test in 2007 if value >7% |
Glucose lowering drug prescription within last 3 months of 2007 |
| Diabetes patients with HbA1c >7% not on maximum treatment receiving glucose lowering treatment intensification |
First HbA1C test in 2007 if value >7% |
Glucose lowering drug start or dosage increase within 180 days after baseline test |
| Diabetes patients with HbA1c >8.5% not on maximum treatment receiving glucose lowering treatment intensification |
First HbA1c test in 2007 if value >8.5% |
Glucose lowering drug start or dosage increase within 180 days after baseline test |
|
Low-density lipoprotein cholesterol (LDL-C)
|
|
|
| Diabetes patients with LDL-C test who are treated with lipid lowering drugs |
First LDL-C test in 2007 |
Lipid lowering drug prescription within last 3 months of 2007 |
| Diabetes patients with LDL-C >2.5 mmol/l not on maximum treatment receiving lipid lowering treatment intensification |
First LDL-C test in 2007 if value >2.5 mmol/l |
Lipid lowering drug start or dosage increase within 180 days after baseline test |
| Diabetes patients with LDL-C >3.5 mmol/l not on maximum treatment receiving lipid lowering treatment intensification |
First LDL-C test in 2007 if value >3.5 mmol/l |
Lipid lowering drug start or dosage increase within 180 days after baseline test |
|
Systolic blood pressure (SBP)
|
|
|
| Diabetes patients with SBP ≥140 mm Hg who are treated with blood pressure lowering drug(s) |
First SBP test in 2007 if value ≥140 mm Hg |
Blood pressure lowering drug prescription within last 3 months of 2007 |
| Diabetes patients with SBP ≥140 mm Hg not on maximum treatment receiving blood pressure lowering treatment intensification |
First SBP test in 2007 if value ≥140 mm Hg |
Blood pressure lowering drug start or dosage increase within 180 days after baseline test |
| Diabetes patients with SBP ≥160 mm Hg not on maximum treatment receiving blood pressure lowering treatment intensification |
First SBP test in 2007 if value ≥160 mm Hg |
Blood pressure lowering drug start or dosage increase within 180 days after baseline test |
| Diabetes patients with 2 sequential SBP ≥140 mm Hg receiving blood pressure lowering treatment intensification |
First SBP test in 2007 with value ≥140 mm Hg |
Blood pressure lowering drug start or dose increase within 180 days after baseline test |
| Diabetes patients with 2 sequential SBP ≥160 mm Hg receiving blood pressure lowering treatment intensification |
First SBP test in 2007 with value ≥160 mm Hg |
Blood pressure lowering drug start or dose increase within 180 days after baseline test |
|
Albumin:creatinine ratio (ACR)
|
|
|
| Diabetes patients with ≥2.5 mg/mmol (males) or ≥3.5 mg/mmol (females) treated with ACE-inhibitors or angiotensin receptor blocker (ARB) |
First ACR test in 2007 if value ≥2.5 mg/mmol (males) or ≥3.5 mg/mmol (females) |
ACE-i or ARB drug prescription within last 3 months of 2007 |
| Patients with ACR ≥2.5 mg/mmol (males) or ≥3.5 mg/mmol (females) receiving ACE-inhibitors or ARB treatment intensification |
First ACR test in 2007 if value ≥2.5 mg/mmol (males) or ≥3.5 mg/mmol (females) |
ACE-i or ARB start or dosage increase within 180 days after baseline test |
